Epidemiology Study - Overview

Migraine Study Objective:

To determine the prevalence and incidence of Migraine among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Migraine within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Adjustments can be made based on the study's scope, available data, and specific research questions of interest.

Migraine Study USP:

• This epidemiological study on Migraine stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.

• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Migraine related health problems.

• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Migraine but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Migraine cases.

Migraine related Study Overview:

The study Defines Migraine as an advanced form of disease. The significance of studying Migraine epidemiology is due to its increasing prevalence in different age populations.

Migraine Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Migraine cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Migraine Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Migraine and potential risk factors (e.g., age, smoking, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Migraine study summary:

Migraine study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Migraine worldwide.

Migraine Disease overview:

Migraine is a neurological disorder characterised by recurrent, throbbing or pulsing intense headaches, mostly on only one side of the patient’s head. Usually, Migraine attacks last for 4 to 72 hours, affecting over 1 billion people globally.

According to international classification of headache disorder, by WHO, there are different types of migraine, 3 most common types are migraine with aura, migraine without aura and migraine aura without headache. Term aura means visual disturbances like coloured spots, blind spots, or flashing lights in front of eyes. Migraine is mostly considered as ‘episodic’ if the patient get symptoms in one or 14 days in every month and called chronic if symptoms occur on 15 or more days per month.

Global prevalence of migraine is about 10 % including 6% for males and 14% for females. Prevalence is observed to be varying in different regions globally, highest in Europe about 15%, in North America 13%, and found to be lower in Asia with 9% and Africa about 5%.

Various treatment options are available for the treatment of acute (abortive) medications or preventive (prophylactic) medications. Several key players manufacturing the therapeutics for migraine are Abbott, Aerial BioPharma LLC., Astellas Pharma India Private Limited, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Global Information, Inc., Horizon Pharma plc., Johnson & Johnson Services, Inc, Merck & Co., Pfizer Inc, Teva Pharmaceutical Industries Ltd, Winston Pharmaceuticals, Inc., Zogenix, Inc.

This review discusses key aspects of the prevalence and incidence of Migraine, it also examines factors known to modify risk, including demographic and environmental influences. Understanding the global epidemiology of Migraine is essential for effective prevention and management strategies for affected patients.

Migraine Demographic and Environmental Risk Factors:

Age and sex: Mostly migraine begins at puberty, affecting mainly those aged between 35 and 45 years. Seen to be more common in females, due to the hormonal influences. Children often experience migraine for short period of time. In U.S. women are more likely to face with migraine 3 times more than men. It is observed that every year 17% women suffer with migraine attacks in comparison with 6% men. The migraine prevalence is higher in females, compared with males, in all age groups. According to 2019 data, the global age-standardized prevalence rate in females and males were 17,902.5 that is 95% and 10,337.6, about 95% per 100,000 populations. Highest incidence cases were reported in range of 10 to 14 age group, for both male and females.

Ethnicity: According to MRFR analyses, prevalence of migraine was highest in Caucasians, about 20.4% than in African with 16.2% or Asian with 9.2% Americans. Same kind of pattern was observed for men with 8.6%, 7.2% and 4.2%. African Americans were more likely to report higher levels of headache pain than any other issues like vomiting or nausea with their attacks, in opposite, African Americans were less disabled by their attacks than Caucasians, and no statistically significant difference associated features between Asian American and Caucasian migraineurs.

Risk Factors causing Migraine: Factors including stress, lack of sleep, Fasting, sensory stimuli (auditory) or hormonal changes, skipping meals, alcohol, changes in weather, barometric pressure, bright sunlight, flickering lights, air quality, noise are some of the common triggering factors or causing factors of migraine.

Migraine Market Scope:

Drivers: Increasing prevalence of migraine worldwide, lifestyle changes, stress, poor sleep, dietary factors contribute to rise in burden of this health condition. Advancement in drug development for the treatment of migraine, increased awareness about the symptoms of the disease, leading to earlier diagnosis, emerging healthcare options like telemedicine are all the drivers of the global migraine market, advancing progress towards more effective and personalized treatment solutions.

Restraints: Limited treatment efficacy, inadequate symptoms management, high cost of new treatment options causing limited access to certain patient population, side effects of the therapeutics used in treatment, misdiagnosis as tension headaches are some of the major challenges hampering the growth of global migraine market.